Quarterly ResultAug 6, 2026, 08:08 AM
SAB Biotherapeutics Raises $88.7M; Q2 Net Loss $(22.5)M
AI Summary
SAB Biotherapeutics reported a net loss of $(22.5) million for the second quarter of 2026, an increase from $(10.1) million in the prior year period. Despite the higher net loss, diluted loss per share improved to $(0.28) from $(1.09) due to a significant increase in shares outstanding. The company successfully raised $88.7 million through a public offering in March 2026, which is expected to cover operating cash needs for at least the next twelve months and support ongoing clinical development, including the Phase 2b trial for SAB-142.
Key Highlights
- Raised $88.7 million from a public offering in March 2026.
- Q2 2026 net loss was $(22.5) million, compared to $(10.1) million in Q2 2025.
- Diluted loss per share improved to $(0.28) in Q2 2026 from $(1.09) in Q2 2025.
- Research and development expenses increased to $16.2 million in Q2 2026.
- Total assets grew to $238.2 million as of June 30, 2026.
- Total stockholders' equity increased to $214.8 million as of June 30, 2026.
- Net cash used in operating activities was $(24.1) million for six months.
Price Impact
More from SABS